# FDA approves durvalumab for limited-stage small cell lung cancer

Source: [What's New: Drugs RSS Feed](http://www.fda.gov/drugs/cancer-approvals/fda-approves-durvalumab-limited-stage-small-cell-lung-cancer) · 2026-11-07 · Medicine
Page: https://themorning.science/story/fda-approves-durvalumab-for-limited-stage-small-cell-lung-cancer-aa633f775393eaed
Kind: launch · Impact: medium

## In brief

- On December 4, 2024, the FDA approved durvalumab (Imfinzi, AstraZeneca) for limited-stage small cell lung cancer.
- The approval covers adults whose disease has not progressed after concurrent platinum-based chemotherapy and radiation therapy.
- The sources provide no trial data, survival figures or safety details.

## Why it matters

It adds an approved immunotherapy option for a specific group of limited-stage small cell lung cancer patients, which is relevant to oncology researchers and clinicians following treatment guidelines.

## Timeline

- 2024-12-04: FDA approves durvalumab for adults with limited-stage small cell lung cancer whose disease has not progressed after concurrent platinum-based chemotherapy and radiation therapy

## Coverage

- [FDA approves durvalumab for limited-stage small cell lung cancer](http://www.fda.gov/drugs/cancer-approvals/fda-approves-durvalumab-limited-stage-small-cell-lung-cancer) — What's New: Drugs RSS Feed, 2026-11-07

Tags: oncology, drug-approval, small-cell-lung-cancer, durvalumab, fda

---

Brief generated by AI (claude-haiku-5-5) from the reporting listed under Coverage. Headlines belong to their publishers. The Morning Science – https://themorning.science